These results extend our understanding of Src signaling in cancer and provide evidence that p300 cooperates with nuclear Src to promote pancreatic cancer progression and together represent an effective target for anti-invasive therapies in pancreatic cancer, a disease characterized by its high degree of invasiveness and mortality. This evidence concerns the gene SRC and familial pancreatic carcinoma.